Verastem’s KRAS G12D inhibitor delivers an early pancreatic cancer signal
Verastem Oncology is staking its near-term future on VS-7375, and the first readout from the phase 1/2 study gives the company a far stronger argument than many developers ever get with a first-in-class oncology program. In advanced KRAS G12D-mutated solid tumors, the oral inhibitor produced response data in metastatic pancreatic ductal adenocarcinoma and non-small cell lung cancer that are drawing sharp attention across the field.
The most compelling numbers came from the pancreatic cohort. Among 22 evaluable patients with metastatic pancreatic ductal adenocarcinoma who received 900 mg daily, six-month progression-free survival was 67% and overall survival was 80%. Sixteen of those patients were still receiving treatment at the six-month mark. In a disease where systemic relapse is the rule and durable disease control has been difficult to achieve, sustained treatment exposure can matter as much as the headline response rate.
A separate efficacy cut in second-line pancreatic cancer added another layer. Half of the eight patients treated in the second-line setting responded, and among 22 patients treated in the second-line setting or later, the response rate was 41%, including two complete responses. Those complete remissions are particularly striking in metastatic pancreatic cancer, where complete radiographic clearance is uncommon and typically reserved for a very small fraction of patients receiving active systemic therapy.
The lung cancer cohort also showed activity. Among 23 patients with NSCLC who received 600 mg daily, the confirmed objective response rate was 43% at 4.4 months, with a six-month progression-free survival rate of 72%. In a setting where KRAS-driven tumors have long resisted targeted control, an oral inhibitor that can produce early and measurable shrinkage in a meaningful fraction of patients is not a trivial event.
Why KRAS G12D remains such a difficult target
KRAS sits at the center of a signaling switchboard that controls cell growth and division. When mutated, it can lock cells into a proliferative state and help drive malignant transformation. G12D is the single most prevalent KRAS mutation in human cancers, accounting for 26% of all KRAS mutations, which explains why drug developers keep returning to it despite years of setbacks.
VS-7375 was designed as an oral selective KRAS G12D inhibitor that engages both the active, or ON, state and the inactive, or OFF, state of the target. That dual-state design is biologically relevant because KRAS signaling does not sit still; tumors can cycle between conformations, and a drug with broader state engagement may have a better chance of suppressing downstream growth signals across heterogeneous cancer cells. In pancreatic cancer, where dense stroma, adaptive resistance, and rapid clonal evolution all complicate treatment, a mechanism with that breadth is more than an academic detail.
The timing of the readout also matters in commercial terms and in clinical terms. Verastem had redirected its research and development priorities toward VS-7375 after its approved ovarian cancer combination, Avmapki and Fakzynja, underperformed in a pancreatic study. The new data do not erase the uncertainty of early development, but they do give the company a much stronger rationale for that pivot than the earlier program could provide.
One number in particular will attract attention from oncologists: a 50% response rate in the small second-line pancreatic subgroup. Small cohorts can magnify variability, and the sample is too limited to support broad conclusions. Even so, responses of that magnitude in metastatic pancreatic ductal adenocarcinoma are hard to ignore, especially when paired with six-month survival and treatment retention data that suggest more than a fleeting signal.
Competitive pressure is already building in KRAS-mutant disease
The KRAS space accelerated again in August when Revolution Medicines’ RAS inhibitor Rasonque won FDA approval for metastatic pancreatic cancer. That drug previously produced a 36% confirmed objective response rate in the second-line setting and 21% in the third-line setting and beyond. Against that backdrop, Verastem’s early efficacy cut is being framed internally as a possible new benchmark.
Dan Paterson, Verastem’s chief executive, told investors that the company had “set a new benchmark in PDAC” and suggested, “we have a true blockbuster.” Manuel Hidalgo Medina, director of the gastrointestinal cancer center at New York University, told investors that VS-7375 and KRAS inhibitors more broadly are changing how pancreatic ductal adenocarcinoma is managed and treated. Those are strong words, and the market will judge them against larger, longer follow-up datasets.
The clinical question now is not whether KRAS G12D is biologically actionable. It is whether the response rates can hold as patient numbers rise, dosing continues, and the drug moves into randomized testing against the realities of later-line metastatic disease. Pancreatic cancer has humbled many promising mechanisms before, and even a promising early profile must survive deeper exposure to resistance patterns, tolerability issues, and comparator arms.
Phase 3 planning shifts the pressure from signal to proof
Verastem plans to move VS-7375 into a phase 3 trial and evaluate it as monotherapy and in combination with anti-EGFR therapy or chemotherapy. The goal is to launch the study by the end of the year. That next step will matter because the most important question in oncology drug development is not whether a molecule can induce responses in a limited cohort, but whether it can consistently improve clinically meaningful outcomes in a broader population.
Combination strategy is likely to be central. Anti-EGFR therapy and chemotherapy each attack different biological vulnerabilities, and pairing them with KRAS inhibition could deepen pathway suppression or delay escape through alternative signaling routes. In KRAS-driven tumors, single-node blockade often triggers adaptive feedback, so combination regimens are not a luxury; they are often the route by which a good signal becomes a durable one.
Paterson also pointed to partnering as part of the company’s long-term plan, saying smaller companies can be nimble but cannot do everything large companies can. He added that the ideal deal would enlarge the value of the program. That strategy makes sense for a development-stage company carrying a drug into a costly phase 3 program, especially one competing in a hotly contested molecular class.
For now, the central fact is simple: an oral KRAS G12D inhibitor has shown early activity across advanced solid tumors, with especially notable signals in metastatic pancreatic ductal adenocarcinoma. The next readout will need to show whether those responses persist, whether the safety profile supports broader use, and whether larger cohorts reproduce the same level of disease control in a setting where every increment of progress is hard won.